Back to search

University of Ioannina

Μελέτη βιοχημικών παραμέτρων βρογχοκυψελιδικού εκπλύματος ασθενών με λιπώδη εμβολή

Abstract

dc:description

The Fat Embolism Syndrome (FES) is a posttraumatic complication, which is usually encountered in patients with serious injuries, especially those with pelvic or long bone fractures. It can also occur as a complication during cardiopulmonary resuscitation or lipid infusion used for parenteral feeding.The aim of this study was to investigate the pathogenesis of acute lung injury during FES and to identify diagnostic markers through the evaluation of BAL (Bronchoalveolar Lavage) fluid alterations in trauma patients. In this direction, patients with FES who developed acute hypoxemic respiratory failure requiring mechanical ventilation were studied. BAL characteristics of the patients with FESwere compared to those from patients with acute lung injury — acute respiratory distress syndrome (ALI/ARDS) from other risk factors except FES and from mechanically ventilated patients without cardiopulmonary disease. The major laboratory findings on BAL fluid of patients with fat embolismwhere: 1) increased levels of total protein, phospholipids and neutral lipids, especially of total cholesterol, 2) elevated activities of PLA2, and 3) increased levels of PAF inversely correlated with PAF-AcH. The increased protein levels in BAL fluid of patients with FES were a consistent finding, signifying an increase in alveolar-capillary permeability. This indicates that FES is associated with an alveolar-capillary barrier disorder leading to an acute lung injury with high permeability pulmonary edema. Of note, the increased concentration of protein in the alveolar space could further disturb the biophysical properties of surfactant resulting in hypoxemia. An interesting finding in this study was the prominently high concentration of neutral lipids and especially that of total cholesterol and cholesterol esters in BAL from all FES patients compared to both control and ARDS patients. The origination of neutral lipids is clearly from bone marrow, where they exist in high concentrations. The levels of total cholesterol and cholesterol esters can distinguish FES from ARDS due to other causes. Therefore, the measurement of BAL total cholesterol levels could be a diagnostic tool of FES, at least of those with a manifestation of acute lung injury. Total phospholipid content in the FES was significantly higher compared to both controls and ARDS patients. Total phospholipids were also elevated in ARDS patients in comparison to normal group. In a previous work we have observed an increase of total phospholipids during early ARDS. In both groups, FES and ARDS,the BAL was performed during the first three days, period which is considered as early phase of the disease. This increase of phospholipids in FES could derive first from the bone marrow fat passing into the alveolar space through the increased alveolar-capillary membrane permeability and secondly from a local production, or probably to both. Whether the local increase of phospholipids was caused by an enhanced production, secretion or by a defect in reuptake of phospholipids by type II alveolar cells remains to be elucidated. It is known that hyperventilation promotesphospholipid production by acetylcholine or beta-adrenergic agonists-mediated mechanisms. Finally, PAP, according to some investigators could increase surfactant production and/or secretion. It is of note that PAF was found in very high levels in BAL fluid from FES compared to both control and ARDS patients. The qualitative alterations of surfactant were similar with those of ARDS patients. The decrease of PC could be attributed to a dysfunction of type Π alveolar cells, which are the main cellular source for these phospholipids. These alterations could directly affect surfactant biophysical activity. Elevated PAF levels could be related to a local inflammatory reaction. PAF could be implicated in pulmonary edema formation because of its ability to cause micro vascular leaking, to stimulate biosynthesis of potent inflammatory mediators, as well as to induce pulmonary venous vasoconstriction increasing the pulmonary capillary pressure. PAF binding to cell surface receptor could regulate recruitment, activation and adhesion of neutrophils. It is synthesized by a variety of cells including alveolar macrophages, neutrophils and alveolar epithelial cells and acts locally, because it is rapidly inactivated by the circulating PAF-AcH. PAF-AcH plays a major role in the potential for PAF to function as an autacoid. The feet that PAF-AcH has inverse correlation with PAF may suggest that PAF-AcH is also locally produced. The feet that no correlation was found between PAF and PAF-AcH in ARDS patients from other reasons is not well understood. One explanation could be that in ARDS patients the majority of PAF-AcH was originating from plasma, where it exits in high concentrations. The production of PAF is also regulated by phospholipase A2, which was increased in FES as well as in ARDS patients compared to controls. Phospholipase A2 can affect pulmonary function either directly, by hydrolyzing lung surfactant phospholipids and increasing surface tension or indirectly, through the production of biologically active molecules such asplatelet-activating factor (PAF), lyso-phosphatidylcholine and eicosanoids. PLA2 could be produced locally by inflammatory cells and secreted into the alveolar space. Alveolar macrophages are also considered as major source of PLA2 in the lung. In addition, various cell types, such as platelets, mast cells, fibroblasts, macrophages and neutrophils produce and secrete PLA2 following stimulation. The involvement of phospholipase A2 in ARDS has been shown in a study with animal models where the enzyme was increased in correlation with the severity of lung injury. The high levels of lyso-phosphatidylcholine in our patients with FES strongly indicate that PLA2 is implicated in the pathogenesis of the syndrome, given that PLA2 catalyses the degradation of PC to lyso-PC and free fatty acids. Against our expectations though, the percentage of free fatty acids in our patients with FES was lower compared to ARDS group, although it was higher than in our normalgroup. One explanation for this could be the transacylation of free fatty acids to cholesterol esters (possibly via acyl-CoA-cholesterol acyltransferase), which were found to be significantly increased. The free fatty acids used as substrates in this procedure could possibly derive: 1) from triglycerides which are converted to monoglycerides through a triglyceride lipase activatioa This interpretation is in consistence to the increased monoglycerides and the decreased triglycerides in BAL from our patients with FES compaired to both controls land 2 2) from phospholipids and especially from PC due to the increased phospholipase A2 activity. Of note, PC was decreased in FES patients in comparison with our normal group. In conclusion, the high levels of protein concentration in BAL fluid from FES patients strongly suggests an increased capillary-alveolar membrane permeability.This confirms that FES is a risk factor for acute lung injury. The increased capillaryalveolar membrane permeability could also be an explanation for the observed increase of total phospholipids. This increase of total phospholipids could also signify an increase of surfactant production and/or secretion by type II alveolar cells. The stimulation of type II cells could be mechanical or chemical. The increased levels of PLA2 activity, leading to changes in the lipid profile of BAL fluid, indicate activation of enzymic or oxidation processes. Therefore, PLA2 as well as PAF-AcH could play an important role in the development or down-regulation of inflammation Iin FES, respectively. Finally, the increase of neutral lipids and especially cholesterol and esters in BAL fluid could be a significant diagnostic tool and might clearly distinguish patients with FES from controls and those with ARDS.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2005

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Karageorga, Georgia
  • Καράγιωργα, Γεωργία

Subjects

dc:subject × 11

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/34260

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Karageorga, Georgia; Καράγιωργα, Γεωργία. Μελέτη βιοχημικών παραμέτρων βρογχοκυψελιδικού εκπλύματος ασθενών με λιπώδη εμβολή. University of Ioannina, 2005. http://hdl.handle.net/10442/hedi/34260